Patients with HCC included into the present study were treated before 2017 and thus immunotherapy and the vascular endothelial growth factor receptor (VEGFR) targeted antibody bevacizumab, potentially having some intracranial activity, not yet used. Here, KDR is linked to hepatocellular carcinoma.